A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals (Q43042364)

12 November 2017

title

A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals (English)

1 reference

12 November 2017

3

1 reference

12 November 2017

Bonaventura Clotet Sala

series ordinal

2

object named as

Bonaventura Clotet

1 reference

12 November 2017

Sandra Franco

1

1 reference

12 November 2017

publication date

26 November 2007

1 reference

12 November 2017

1 reference

12 November 2017

volume

131

1 reference

12 November 2017

issue

2

1 reference

12 November 2017

page(s)

260-270

1 reference

From structure to function: new insights into hepatitis C virus RNA replication

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Genetic organization and diversity of the hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Fitness landscape of human immunodeficiency virus type 1 protease quasispecies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Genetic and catalytic efficiency structure of an HCV protease quasispecies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

The therapeutic potential of NS3 protease inhibitors in HCV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Recent development of therapeutics for chronic HCV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Complete replication of hepatitis C virus in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Structure of the catalytic domain of the hepatitis C virus NS2-3 protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Genetic screen for monitoring hepatitis C virus NS3 serine protease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Replication of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Robust hepatitis C virus infection in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

Kinetic and structural analyses of hepatitis C virus polyprotein processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.10.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIRUSRES.2007.10.003

1 reference

12 November 2017

1 reference